Sujata M Bhavnani

Summary

Publications

  1. pmc Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 56:1065-72. 2012
  2. pmc Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 60:1600-7. 2015
  3. pmc Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 59:372-80. 2015
  4. pmc Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model
    Anthony M Nicasio
    Albany College of Pharmacy and Health Sciences, Albany, New York, USA
    Antimicrob Agents Chemother 60:2075-80. 2016
  5. doi request reprint Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Latham, NY 12208, USA
    Diagn Microbiol Infect Dis 63:155-9. 2009
  6. pmc Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 56:130-6. 2012
  7. pmc Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 56:1466-70. 2012
  8. pmc Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 57:6348-50. 2013
  9. doi request reprint Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead
    Brian T Tsuji
    School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, New York, USA
    Clin Infect Dis 52:S513-9. 2011
  10. pmc Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables
    Jeffrey P Hammel
    Cognigen Corporation, Buffalo, New York, USA
    Antimicrob Agents Chemother 50:62-7. 2006

Collaborators

Detail Information

Publications38

  1. pmc Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 56:1065-72. 2012
    ..5 and 0.25 mg/liter versus 16 and 1 mg/liter for VAP versus non-VAP patients, respectively; P = 0.006). These findings demonstrated the impact of pharmacological and patient-specific factors on the clinical and microbiological responses...
  2. pmc Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 60:1600-7. 2015
    ..The risk of CPK elevation, which is reversible, should be weighed in the context of the mortality and severe morbidity associated with these types of serious staphylococcal infections. ..
  3. pmc Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 59:372-80. 2015
    ..aureus infections. Results of these analyses confirm that a ceftaroline fosamil dosing regimen of 600 mg every 12 h provides exposures associated with the upper plateau of the pharmacokinetic-pharmacodynamic relationship for efficacy. ..
  4. pmc Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model
    Anthony M Nicasio
    Albany College of Pharmacy and Health Sciences, Albany, New York, USA
    Antimicrob Agents Chemother 60:2075-80. 2016
    ..These data provide important information for the development of β-lactam-β-lactamase inhibitor combination agents. ..
  5. doi request reprint Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Latham, NY 12208, USA
    Diagn Microbiol Infect Dis 63:155-9. 2009
    ..25 mg/L. The median probability of microbiologic success was 66% or less for MIC values of 0.5 mg/L or greater. These data support a susceptibility breakpoint of 0.25 mg/L for S. aureus and streptococci...
  6. pmc Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 56:130-6. 2012
    ..004). Although statistically significant, the linear relationship between tigecycline exposure and maximum change from baseline in total bilirubin is unlikely to be clinically significant...
  7. pmc Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 56:1466-70. 2012
    ..Additionally, as demonstrated by using pharmacokinetic-pharmacodynamic data, the magnitude of the treatment effect for patients with HAP is large...
  8. pmc Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 57:6348-50. 2013
    ..As a result, significant PK-PD relationships could not be identified. These data provide support for the use of a ceftaroline fosamil dosing regimen of 600 mg i.v. q12h to treat patients with CABP. ..
  9. doi request reprint Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead
    Brian T Tsuji
    School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, New York, USA
    Clin Infect Dis 52:S513-9. 2011
    ..Herein, we review the data supporting the use of this novel fusidic acid dosing regimen, which will undergo further clinical evaluation in phase 3 clinical trials...
  10. pmc Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables
    Jeffrey P Hammel
    Cognigen Corporation, Buffalo, New York, USA
    Antimicrob Agents Chemother 50:62-7. 2006
    ..5% of cases for the CR approach. When censored MIC data are modeled, CR may reduce or eliminate biased parameter estimates obtained by SR...
  11. pmc Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208, USA
    Antimicrob Agents Chemother 51:4085-9. 2007
    ..15 (0.561 and 5.23), respectively. Simulation results predict that tissue penetration varies considerably and likely explain unexpected clinical outcomes for those patients infected with strains at margins of the MIC distribution...
  12. pmc Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Antimicrob Agents Chemother 51:4351-5. 2007
    ..Sensitivity analyses suggest that the probability of PK-PD target attainment in adults and children is not affected by increases in MICs for strains of B. anthracis to levels as high as 0.5 mg/liter...
  13. doi request reprint Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206 1072, USA
    Diagn Microbiol Infect Dis 62:99-101. 2008
    ..Such data may be useful to establish prior expectations for the no-treatment effect when conducting noninferiority clinical trials...
  14. ncbi request reprint Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Clin Infect Dis 44:79-86. 2007
    ..Over the past 15 years, considerable PK-PD data have been derived from infected patients for many classes of antimicrobial agents. These data provide the opportunity to confirm knowledge gained from animal PK-PD infection models...
  15. pmc Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Inc, Albany, New York, USA
    Antimicrob Agents Chemother 53:4422-8. 2009
    ..These results suggest that dose modification may be warranted in patients weighing >110 kg. However, the mild nature of the observed relationships for Vc suggest that dosing adjustments are not necessary for elderly patients...
  16. pmc Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model
    Brian Vanscoy
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 57:4134-8. 2013
    ..These data support the selection of ceftolozane-tazobactam dosing regimens that minimize the potential for on-therapy drug resistance amplification. ..
  17. doi request reprint Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, New York, USA
    Clin Infect Dis 50:1568-74. 2010
    ....
  18. pmc Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model
    Brian Vanscoy
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 57:2809-14. 2013
    ..These data provide an initial target tazobactam concentration-time profile and a paradigm to optimize tazobactam dosing when combined with ceftolozane...
  19. pmc Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane
    Brian Vanscoy
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 57:5924-30. 2013
    ..84. This simple translational relationship is especially useful as it is directly linked to in vitro susceptibility test results, which are used to guide the clinician's choice of drug and dosing regimen. ..
  20. doi request reprint Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia
    Scott A Van Wart
    Institute for Clinical Pharmacodynamics, Latham, NY, USA
    J Clin Pharmacol 53:1155-67. 2013
    ..Such a PPK model can evaluate dose adjustments for patients with renal impairment and generate ceftaroline exposures for use in pharmacokinetic-pharmacodynamic assessments of efficacy in patients with ABSSSI or CABP. ..
  21. pmc Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model
    Brian D Vanscoy
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 58:6024-31. 2014
    ..These data support the selection of ceftolozane-tazobactam dosing regimens that minimize the potential for on-therapy drug resistance selection. ..
  22. pmc Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, 43 British American Blvd, Latham, NY 12110, USA
    Antimicrob Agents Chemother 54:5180-6. 2010
    ..This model will serve as the basis for estimating tigecycline exposure for pharmacokinetic-pharmacodynamic analyses for efficacy and safety among patients with community- or hospital-acquired pneumonia...
  23. doi request reprint Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients
    Scott A Van Wart
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Latham, NY 12110, USA
    Diagn Microbiol Infect Dis 63:409-14. 2009
    ....
  24. pmc Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae
    Scott A Van Wart
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 58:885-91. 2014
    ..5 mg/liter, respectively. Recommendations for dose adjustments for patients with renal impairment were also supported by the results of these analyses. ..
  25. pmc Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies
    Olanrewaju O Okusanya
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 58:5005-15. 2014
    ..The model-estimated PFT effects were predicted to be sustained to day 28. An additional 0.451-log10 CFU reduction (P=0.022) was estimated on day 14 relative to day 7, with a persistence of effect predicted to day 35...
  26. doi request reprint Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, New York 12110, USA
    Clin Infect Dis 51:S103-10. 2010
    ..Early consideration of these data in development programs will reduce risk not only to sponsors but also, most importantly, to the patients enrolled in the clinical trials...
  27. pmc Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model
    Brian D Vanscoy
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 59:7170-7. 2015
    ..9, 20.9, and 32.8, respectively. These data provide useful information for modernizing and optimizing ZTI-01 dosing regimens for further study. ..
  28. pmc Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model
    Brian D Vanscoy
    Institute for Clinical Pharmacodynamics, Latham, New York, USA
    Antimicrob Agents Chemother 60:3891-6. 2016
    ..3, 86.1, and 444.8, respectively. These data provide a pharmacokinetics-pharmacodynamics (PK-PD) basis for evaluating potential CB-618 dosing regimens in combination with meropenem in future studies. ..
  29. pmc Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models
    Catharine C Bulik
    Institute for Clinical Pharmacodynamics, Schenectady, New York, USA
    Antimicrob Agents Chemother 61:. 2017
    ..Dose-independent PAE durations of 3.07 to 12.5 h and 5.25 to 8.46 h were demonstrated for S. aureus and S. pneumoniae, respectively...
  30. ncbi request reprint Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 60:59-64. 2008
    ..29). Oral gemifloxacin is clinically effective and has an economic advantage over ceftriaxone, followed by oral cefuroxime with or without a macrolide...
  31. pmc Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia
    Sujata M Bhavnani
    Cognigen Corporation, Buffalo, New York, USA
    Antimicrob Agents Chemother 50:994-1000. 2006
    ..84, P = 0.05, when one patient, a medical outlier, was excluded). A similar relationship was found for clinical response. These results will be valuable in supporting dose selection of oritavancin for patients with S. aureus bacteremia...
  32. pmc Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model
    Brian Vanscoy
    Institute for Clinical Pharmacodynamics, Schenectady, New York, USA
    Antimicrob Agents Chemother 60:5141-5. 2016
    ..These data will be useful to support the selection of fosfomycin dosing regimens that minimize the potential for on-therapy amplification of bacterial subpopulations with reduced susceptibility. ..
  33. pmc Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against Itself
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Schenectady, New York, USA
    Antimicrob Agents Chemother 61:. 2017
    ..Such adjunctive therapies hold promise for marked reductions in the tonnage of antimicrobial agents administered to patient populations and selection pressure toward antimicrobial resistance...
  34. pmc Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi
    Brent M Booker
    The University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Applied Pharmacodynamics Labooratory, New York, USA
    Antimicrob Agents Chemother 49:1775-81. 2005
    ....
  35. doi request reprint Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection
    Olanrewaju O Okusanya
    Institute for Clinical Pharmacodynamics, Latham, NY 12110, USA
    Diagn Microbiol Infect Dis 70:101-11. 2011
    ....
  36. pmc Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection
    Olanrewaju O Okusanya
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Inc, Albany, New York, USA
    Antimicrob Agents Chemother 53:3847-54. 2009
    ..Together, these findings likely represent drug effect and warrant the further development of liposomal amikacin for inhalation...
  37. ncbi request reprint Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 54:231-6. 2006
    ..Although infections arising from E. coli and Klebsiella species are associated with significant mortality, ESBL production alone did not appear to be an independent risk factor for treatment failure...
  38. ncbi request reprint Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Pharmacotherapy 25:717-40. 2005
    ....